As healthcare professionals, we strive to provide the best possible care for people with type 1 diabetes. One of the most challenging aspects of managing this condition is achieving and maintaining blood glucose levels within a safe and healthy range. The development of hybrid closed-loop systems, which combine continuous glucose monitoring and insulin pump therapy with advanced algorithms to automate insulin delivery, represents a significant advance in diabetes care.

Data from the ABCD worldwide EndoBarrier registry published in the current issue of Diabetes Care

1022 patients, 34 centres, 10 countries, shows improvements in weight, glycaemic control and CVD risk factors. EndoBarrier is a potential future treatment option.

https://diabetesjournals.org/care/article-pdf/46/4/e89/700530/dc221952…

The Diabetes Technology Network UK (DTN-UK) are looking for three people with diabetes, who have personal experience of using wearable diabetes technologies (CGM/pump/closed-loop systems) to join the committee of DTN-UK, part of the Association of British Clinical Diabetologists (ABCD).

DTN-UK is an organisation which exists to support UK health care professionals involved in using technology designed to improve the lives of people living with diabetes.

Endoscopic proximal intestinal exclusion can improve non-alcoholic fatty liver disease (NAFLD) in patients with diabesity.

Presented by: B Hayee

Authors:

Hayee B, Sen Gupta P, Anderson M, Fogden E, Roy AA, Butler DB, Bajwa RS, Amiel SA, Ryder REJ.

Endoscopic proximal intestinal exclusion with Endobarrier bringing simultaneous benefit to both diabesity and obstructive sleep apnoea(OSA) requiring overnight continuous positive airway pressure ventilation(CPAP)- Case reports

Authors:

M Yadagiri, MH Lang, AAS Mohammed, N Nathani, AB Rajasekharan, JP Bleasdale, EN Fogden, MR Anderson, P Sen Gupta, REJ Ryder.

A reminder to ABCD members that voting closes soon (3 April, midday) for the Royal College of Physicians elected councillors.

Two diabetologists are standing for election:

The interaction of endoscopic proximal intestinal exclusion therapy using Endobarrier with GLP-1 therapy rapidly improves type 2 diabetes by increasing fasting and postprandial satiety.

Authors:

P Sen Gupta, RS Drummond, BM McGowan, B Hayee, T Dew, RP Vincent, CW le Roux, JJ Holst, SA Amiel, REJ Ryder

Institution of the UK’s first National Health Service Endobarrier service for type 2 diabetes and obesity.

Authors:

P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, M Anderson and REJ Ryder

UK first NHS Endobarrier service for diabesity: outcomes in the first 30 patients to reach six months after explanation of the device.

Authors:

REJ Ryder, M Yadagiri, SP Irwin, W Burbridge, H Gandhi, RA Allden, JP Bleasdale, EN Fogden, M Anderson and P Sen Gupta

Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes and Obesity.

Authors:

S Armstrong, P Sen Gupta, SA Amiel, RS Drummond, BM McGowan, REJ Ryder, MW Pennington